Skip to main content

Clinically Relevant Immunogenicity: Strategies for Impact on Safety

Thank you

This live web event has ended. Thank you for attending.


  • Kate Peng, Ph.D.

    Peng received her Ph.D. in metabolic biology from the University of California at Berkeley. Following her postdoctoral trainings at Berkeley, Dr. Peng worked at biotechnology industry with a focus on developing cell-based high-throughput screening assays to monitor GPCR activation. Dr. Peng joined Genentech in 2007 and is currently a senior scientist in the Assay Development & Technology (ADT) group of BioAnalytical Sciences (BAS) department. Her focus is on development of bioanalytical strategies and methods to enable assessment of the pharmacokinetics, pharmacodynamics, immunogenicity of protein bio-therapeutics from early development to clinical as well as post-marketing studies. Dr. Peng has led bioanalytical effort for supporting the development of protein bio-therapeutics that target immunology, neurology and cardiovascular disease areas.

  • Scott Hottenstein

    Charles Scott Hottenstein is a Group Leader at GlaxoSmithKline in the Immunogenicity and Clinical Immunology within PTS-IVIVT Bioanalysis, Immunogenicity and Biomarkers. He received his Bachelors degree in Biology from the University of Delaware. Since that time he has specialized in the area of bioanalysis by immunoassay where he was responsible for the development of commercial diagnostics assays for the measurement of hormones and environmental contaminants prior to working with vaccines and large molecule biopharmaceuticals in the pharmaceutical industry for over 25 years. Charles currently manages a group that specializes in the optimization and validation of bioanalytical immunogenicity methods for large molecule biopharmaceuticals supporting preclinical GLP and clinical GCP studies using immunochemical ligand binding techniques.

October 5, 2017
Thu 12:30 PM EDT

Duration 1H 30M

This live web event has ended.